1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited

CUV.AX
Clinuvel Pharmaceuticals LimitedAU flagAustralian Securities Exchange
10.26
AUD
+0.05
- -
517.21MMarket Cap
Clinuvel Pharmaceuticals Limited
CUV.AX
(Australian Securities Exchange)

Recent

price

10.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.03
0.02
0.04
0.06
0.07
0.14
0.35
0.53
0.64
0.66
0.97
1.33
1.59
1.77
1.9
Revenue per Share
-0.38
-0.38
-0.32
-0.19
-0.14
-0.24
-0.07
0.15
0.28
0.38
0.34
0.5
0.42
0.62
0.72
0.72
Basic EPS, GAAP
-0.39
-0.31
-0.33
-0.2
-0.12
-0.1
-0.11
0.21
- -
-0.01
-0.02
-0.02
-0.01
-0.02
-0.11
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.02
0.03
0.03
0.04
0.05
0.05
Dividend per Share
0.8
0.43
0.38
0.36
0.36
0.2
0.3
0.47
0.75
1.16
1.46
1.9
2.3
2.88
3.99
4.65
Book Value per Share
0.87
0.54
0.44
0.39
0.4
0.26
0.39
0.53
0.82
1.18
1.49
1.99
2.54
3.33
4.07
4.81
Tangible Book Value per Share
30
30
31
35
39
43
45
48
48
48
49
49
49
49
50
50
Basic Weighted Avg Shares
- -
1
1
2
2
3
6
17
25
31
33
48
66
78
88
95
Sales/Revenue/Turnover
- -
-1,222.93
-1,425.86
-533.21
-287.73
-386.72
-67.36
40.08
47.66
53.07
34.98
58.83
53.76
56.31
54.44
48.13
Operating Margin (%)
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Depreciation Expense
-12
-11
-10
-7
-6
-10
-3
7
13
18
17
25
21
31
36
36
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.83
39.17
32.85
29.68
29.83
Effective Tax Rate (%)
- -
-1,095.95
-1,351.3
-438.04
-251.17
-357.69
-50.77
42.95
51.89
58.41
51.12
51.54
31.77
39.08
40.41
38.07
Profit Margin (%)
26
16
19
14
15
11
18
25
39
56
68
94
127
164
197
236
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
- -
LT Debt
26
16
14
14
15
11
18
25
39
57
74
99
126
165
203
241
Total Equity
- -
- -
- -
- -
- -
- -
- -
30.97
- -
- -
- -
31.02
18.36
18.75
16.82
13.49
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
39.86
- -
- -
- -
31.26
21.23
25.41
22.62
18.15
Return on Capital (%)
-38.96
-60.93
-78.11
-55.75
-41.58
-92.59
-28.4
39.6
45.21
39.52
26.08
29.88
20.16
23.95
20.91
16.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.49%
26.85%
18.62%
Free Cash Flow
54%
86.3%
-94.65%
Net Income, GAAP
-18.68%
19.5%
1.5%
Sales/Revenue/Turnover
48.55%
24.77%
7.76%
Total Cash Common Dividend
- -
- -
1.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
78
2024
- -
- -
- -
- -
88
2025
- -
- -
- -
- -
95

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.62
2024
- -
- -
- -
- -
0.72
2025
- -
- -
- -
- -
0.72

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.04
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.05
Similar Companies
Verde Science, Inc. (VRCI)
ImmunityBio, Inc. (IBRX)
Nabriva Therapeutics plc (NBRV)
Aspire Biopharma Holdings, Inc. (ASBP)
Boston Therapeutics, Inc. (BTHE)
Viking Therapeutics, Inc. (0VQA.L)
Business
Clinuvel Pharmaceuticals Limited specializes in the development and commercialization of therapies for patients with severe genetic and skin disorders. Its core products and services focus on photoprotection and treatment of conditions caused by photosensitivity, including the FDA-approved drug Scenesse (afamelanotide), which is used to prevent phototoxic reactions in patients with erythropoietic protoporphyria (EPP). The company also develops therapies for other skin disorders and leverage melanocortin-based treatments for rare diseases. Clinuvel operates globally, with a headquarters in Melbourne, Australia, and a presence in Europe, the United States, and Asia. Founded in 1999, Clinuvel Pharmaceuticals has recently made strategic expansions by initiating new clinical programs targeting additional indications such as vitiligo and other photosensitive conditions. The company has formed key partnerships to advance its research pipeline and broaden its market reach. It has also enhanced its manufacturing and distribution capabilities to support global commercialization efforts. These developments reflect Clinuvel’s commitment to expanding its therapeutic portfolio beyond its flagship product while maintaining a focus on rare and underserved patient populations. The company remains publicly traded on the Australian Securities Exchange under the ticker CUV.AX. This combination of specialized products, ongoing innovation, and strategic growth initiatives positions Clinuvel as a prominent player in the pharmaceutical biotech sector dedicated to photomedicine and rare diseases.

Company News

APIChatGPT

  • globenewswire.com

    CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies